Nakata Bunzo, Fukunaga Shinya, Noda Eiji, Amano Ryosuke, Yamada Nobuya, Hirakawa Kosei
Department of Surgical Oncology, Institute of Geriatrics and Medical Science, Osaka City University Graduate School of Medicine, Osaka, Japan.
Oncology. 2008;74(1-2):69-75. doi: 10.1159/000139126. Epub 2008 Jun 11.
The clinical significance of chemokine receptor CCR7 expression in pancreatic ductal cancer was investigated.
Immunohistochemical staining of 89 pancreatic cancers treated macroscopically with curative resection without hematogenous metastases or peritoneal dissemination were analyzed in association with clinicopathological data.
The positivity of CCR7 in pancreatic cancer was 32.6% (29/89). A significant correlation was detected between CCR7-positive expression and lymph node metastasis. Patients with CCR7-positive tumors had significantly shorter survival times than those with CCR7-negative tumors (median, 12.8 vs. 21.9 months, respectively; p = 0.0039). CCR7 expression was an independent prognostic factor (hazard ratio, 1.949; p = 0.0364) by multivariate survival analysis; however, it was not an indicator for any particular site of recurrence.
The survival impact of CCR7 expression on resectable pancreatic cancer may be associated with lymphatic spread. The results from the present study should foster further investigation of treatments using an inhibitor for the CCR7 protein to improve the survival of pancreatic cancer.
研究趋化因子受体CCR7在胰腺癌中的临床意义。
对89例接受根治性切除且无血行转移或腹膜播散的胰腺癌进行免疫组化染色分析，并结合临床病理数据。
胰腺癌中CCR7的阳性率为32.6%（29/89）。CCR7阳性表达与淋巴结转移之间存在显著相关性。CCR7阳性肿瘤患者的生存时间明显短于CCR7阴性肿瘤患者（中位数分别为12.8个月和21.9个月；p = 0.0039）。多因素生存分析显示CCR7表达是一个独立的预后因素（风险比，1.949；p = 0.0364）；然而，它并非任何特定复发部位的指标。
CCR7表达对可切除胰腺癌生存的影响可能与淋巴转移有关。本研究结果应促进进一步研究使用CCR7蛋白抑制剂进行治疗，以提高胰腺癌患者的生存率。
